Niacinamide for Health & Longevity - Quick Reference Sheet

Niacinamide for Health & Longevity

Created on 10/21/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

Niacinamide, an inexpensive form of vitamin B3 sold as an oral supplement and skin-care ingredient, is studied for skin and eye health. Strongest support is fewer new sun-related skin cancers in people who have had several, lasting only during use. Topical support for appearance and acne is moderate. Glaucoma eye protection is unproven; slowing aging is not supported in humans. At studied doses, digestive upset is the main side effect. (Full Review)

Protocol

Skin-cancer prevention
500 mg twice daily
Oral, morning and evening with meals; at least 12 months
Upper intake level
900 mg/day
EFSA adult limit; the 1 g/day skin-cancer regimen slightly exceeds it
Topical use
5% cream twice daily
For skin aging; 4% gel twice daily for acne
Time to effect
Topical skin and acne
8–12 weeks
Skin appearance and acne effects
Precancerous sun spots
3 months
Reductions at the first 3-month visit with oral use
Retinal function (glaucoma)
6–12 weeks
Retinal function changes; visual preservation unproven

Benefits

Contraindications
  • People with liver disease or a history of liver problems
  • Anyone at doses of 3 g/day or more outside clinical trials with close liver monitoring
  • Adults exceeding the 900 mg/day tolerable upper intake level without medical supervision
  • People on hemodialysis without nephrology oversight
  • Infants
  • Pregnant or breastfeeding women at supplemental doses
Key Interactions
  • Anticonvulsants (carbamazepine, primidone): Caution, monitor drug levels
  • Phosphate binders (drugs that trap dietary phosphate in the gut: sevelamer, calcium acetate): Monitor
  • Liver-stressing drugs (methotrexate, valproate): Monitor (theoretical)
  • Antiplatelet and anticoagulant drugs (blood thinners: aspirin, warfarin) in kidney failure: Caution (theoretical)
  • Glucose-lowering drugs (insulin, metformin): Monitor (theoretical)
  • Proton pump inhibitors (stomach-acid reducers such as omeprazole, esomeprazole): No interaction found
  • Acetaminophen at high doses: Monitor (theoretical)
  • Niacin (nicotinic acid, inositol hexanicotinate): Avoid substituting or stacking at high doses
  • Other vitamin B3 forms (nicotinamide riboside, nicotinamide mononucleotide): Monitor (theoretical)
  • Supplements that also stress the liver (green tea extract, kava): Caution (theoretical)
  • Methyl donors (betaine, folate): Possibly favorable (theoretical)
  • Pyruvate: No adverse interaction reported
  • Alcohol: Monitor (theoretical)
  • Chemical sunscreens (octinoxate, ethylhexyl triazone) formulated with niacinamide: Caution (theoretical)

Risk & Side Effects

  • High: Digestive upset; low platelet count in dialysis patients
  • Medium: Itching in dialysis patients; anemia in dialysis patients; shingles in dialysis patients
  • Low: Liver injury at high doses; reduced insulin sensitivity; cardiovascular risk from breakdown products
  • Speculative: Methyl-group depletion and homocysteine rise; blunting of stress-response enzyme activity; greater skin absorption of sunscreen filters; tumor promotion

Monitoring

Marker Target Why
ALT, AST Within laboratory range, ALT roughly 7–55 U/L Safety check: a rise prompts dose reduction or stopping
Platelet count 150–450 × 10⁹/L Safety check in kidney failure: a fall prompts review
Serum phosphate 2.5–4.5 mg/dL Expected to change in dialysis patients
Fasting glucose 70–99 mg/dL Safety check: a rise may reflect reduced insulin sensitivity
Homocysteine About 5–15 µmol/L Expected to change: methyl-group use may raise it
Serum creatinine About 0.6–1.3 mg/dL Safety check: reduced kidney function raises platelet and accumulation risk
New skin cancers and actinic keratoses (dermatologist examination) No established target; track new-lesion count against the prior year Expected to change: fewer new lesions indicate response
Visual field and OCT (glaucoma) No established target; track change from own baseline Expected to change: stability indicates response

Cadence: Baseline panel before starting; recheck 3 months after starting or any dose increase, then every 6–12 months at doses up to 1 g/day and every 3 months at higher doses. Dialysis patients recheck platelets and phosphate monthly for the first three months. Skin examinations every 3–6 months; glaucoma testing at the usual eye-care interval.

Qualitative Assessment

  • Digestive comfort (nausea, bloating, stool changes)
  • Skin texture, new rough or scaly spots, and overall signs of sun-related skin aging
  • Visual clarity, contrast and glare tolerance in glaucoma
  • Energy levels and any unusual fatigue, itching or yellowing that may signal liver stress
  • Easy bruising or bleeding in people with kidney disease